Divi's Laboratories Ltd.
DIVISLAB · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹3,359.85.
Piotroski F-score 3/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%16.2%
- ✓Low debt (D/E < 0.5)0.00x
- ✕Positive free cash flow
- ✕Revenue growth > 10%10%
- ✓Earnings growing14%
- ✓Net margin ≥ 10%24.3%
- ✓Current ratio > 1.55.43
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 34.18
- ✕Piotroski ≥ 73/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Healthy profit margin (24.3%).
- •Financially solid — Altman Z 34.18.
Weaknesses
- •Weak Piotroski score (3/9).
Threats
- •Rich valuation versus sector peers.
- •Trades ~36% above our estimated fair value.
About Divi's Laboratories Ltd.
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, diet
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.